New osteosarcoma treatment receives rare pediatric disease designation from the FDA

(Medical University of South Carolina) Innova Therapeutics Inc. recently announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation for IVT-8086 for the treatment of osteosarcoma. MUSC Hollings Cancer Center researcher Nancy Klauber-DeMore, M.D., was instrumental in the development of the research that led to the therapy.